Clinical Trials Logo

Psoriasis clinical trials

View clinical trials related to Psoriasis.

Filter by:
  • Suspended  
  • Page 1

NCT ID: NCT05332704 Suspended - Plaque Psoriasis Clinical Trials

Safety, Tolerability, PK, PD and Preliminary Efficacy of ONO-4685

Start date: March 25, 2022
Phase: Phase 1
Study type: Interventional

This is an early phase study to assess the safety and tolerability of ONO-4685 in patients with psoriasis. In addition, the study will assess how the drug is distributed and eliminated by the body (pharmacokinetics) and how the drug affects the body (pharmacodynamics). This will be done by measuring the amount of drug in the blood and measuring other markers in the body that might have been affected by ONO-4685. The study will also look at preliminary information on whether ONO-4685 might be effective in treating psoriasis. The study will be split into three parts. Part A will assess a single dose of ONO-4685 in small groups of patients, each group planned to receive a higher dose than the last group. In Part B and C, patients will receive multiple doses of ONO-4685 over a period of 4 weeks.

NCT ID: NCT04121143 Suspended - Plaque Psoriasis Clinical Trials

A Clinical Study of SHR-1314 Injection in the Treatment of Moderate to Severe Plaque Psoriasis in Adults

Start date: November 9, 2019
Phase: Phase 2
Study type: Interventional

This is a multicenter, placebo-controlled, parallel-randomized, double-blind, phase II study to investigate the efficacy, safety, tolerability and Pharmacokinetics of SHR-1314 injection with moderate to severe plaque psoriasis in adults

NCT ID: NCT02394301 Suspended - Psoriasis Clinical Trials

Efficacy of Novel Drug-combinations for Relief of Psoriasis

ENDURE
Start date: February 2015
Phase: N/A
Study type: Observational [Patient Registry]

ENDURE is a prospective, observational study aimed to document clinical response and side effects associated with compounded psoriasis medications when prescribed as routine care. As a secondary initiative, this study will assess methotrexate systemic absorption and toxicity in patients prescribed a methotrexate-containing compounded formulation.

NCT ID: NCT01368887 Suspended - Psoriasis Clinical Trials

Study to Test the Effectiveness of a New Treatment for Scalp Psoriasis

Start date: April 2013
Phase: Phase 2
Study type: Interventional

The purpose of this study is to test the effectiveness of DermiPsor's DPS-102 (test product) in patients with scalp Psoroasis. The study is also intended to assess the safety of the product.

NCT ID: NCT01279629 Suspended - Plaque Psoriasis Clinical Trials

Open Clinical Study, Comparing Non-inferiority of Chronic Plaque Psoriasis

MED
Start date: February 2011
Phase: N/A
Study type: Observational

The purpose of this study is: To evaluate the efficacy of the drugs under study for treating chronic plaque psoriasis. - Population: 50 patients will be selected from both sexes, healthy, between 18 and 65 years with a clinical diagnosis of chronic plaque psoriasis with PASI <20%, according to the criteria of inclusion and exclusion.

NCT ID: NCT01228656 Suspended - Plaque Psoriasis Clinical Trials

Effectiveness of Association Mometasone Furoate 0.1% and Salicylic Acid 5% Compared With Mometasone Furoate

Psoriasis
Start date: September 2006
Phase: Phase 2
Study type: Interventional

The aims is to evaluate the efficacy and comparative isolation of the association Mometasone furoate + Salicylic Acid and the substance isolated Mometasone furoate produced by the Laboratory Glenmark Pharmaceuticals Ltd. in patients of both sexes, patients with plaque psoriasis grade mild to moderate.

NCT ID: NCT01137032 Suspended - Psoriasis Clinical Trials

Study to Evaluate Effect of Pandel Cream 0.1% on HPA Axis in Pediatric and Adult Population

Start date: June 2004
Phase: Phase 4
Study type: Interventional

The purpose of this study is to determine the effect of Pandel® (hydrocortisone probutate cream) Cream 0.1% on the Hypothalamic Pituitary Adrenal (HPA) axis in pediatric and adult subjects with either psoriasis or atopic dermatitis involving greater than 20% body surface area.